This
page
is
part
of
the
FHIR
Specification
(v4.0.1:
R4
(v5.0.0:
R5
-
Mixed
Normative
and
STU
)
).
This
is
the
current
published
version
in
it's
permanent
home
(it
will
always
be
available
at
this
URL).
The
current
version
which
supercedes
this
version
is
5.0.0
.
For
a
full
list
of
available
versions,
see
the
Directory
of
published
versions
.
Page
versions:
R5
R4B
R4
Using
Codes
Code
Systems
Value
Sets
Concept
Maps
Identifier
Systems
Biomedical
Research
and
Regulation
Work
Group
|
Maturity Level : 1 | Draft |
Use
Context
:
|
Official
URL
:
http://hl7.org/fhir/ValueSet/research-study-phase
|
|
|||
| draft as of 2020-12-28 |
|
|||
|
|
|
|||
This value set is used in the following places:
This
value
set
includes
codes
from
Codes
for
the
following
code
systems:
stage
in
the
progression
of
a
therapy
from
initial
experimental
use
in
humans
in
clinical
trials
to
post-market
evaluation.
http://terminology.hl7.org/CodeSystem/research-study-phase
http://hl7.org/fhir/research-study-phase
This
expansion
generated
01
Nov
2019
26
Mar
2023
This value set contains 8 concepts
Expansion
based
on
http://terminology.hl7.org/CodeSystem/research-study-phase
version
4.0.1
All
codes
from
system
http://terminology.hl7.org/CodeSystem/research-study-phase
ResearchStudy
Phase
Code
System
v5.0.0
(CodeSystem)
| Code | System | Display | Definition |
| n-a | http://hl7.org/fhir/research-study-phase | N/A |
Trials without phases (for example, studies of devices or behavioral interventions). |
| early-phase-1 | http://hl7.org/fhir/research-study-phase | Early Phase 1 |
Designation for optional exploratory trials conducted in accordance with the United States Food and Drug Administration's (FDA) 2006 Guidance on Exploratory Investigational New Drug (IND) Studies. Formerly called Phase 0. |
| phase-1 | http://hl7.org/fhir/research-study-phase | Phase 1 |
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients. |
| phase-1-phase-2 | http://hl7.org/fhir/research-study-phase | Phase 1/Phase 2 |
Trials that are a combination of phases 1 and 2. |
| phase-2 | http://hl7.org/fhir/research-study-phase | Phase 2 |
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks. |
| phase-2-phase-3 | http://hl7.org/fhir/research-study-phase | Phase 2/Phase 3 |
Trials that are a combination of phases 2 and 3. |
| phase-3 | http://hl7.org/fhir/research-study-phase | Phase 3 |
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug. |
| phase-4 | http://hl7.org/fhir/research-study-phase | Phase 4 |
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use. |
See the full registry of value sets defined as part of FHIR.
Explanation of the columns that may appear on this page:
| Lvl | A few code lists that FHIR defines are hierarchical - each code is assigned a level. For value sets, levels are mostly used to organize codes for user convenience, but may follow code system hierarchy - see Code System for further information |
| Source | The source of the definition of the code (when the value set draws in codes defined elsewhere) |
| Code | The code (used as the code in the resource instance). If the code is in italics, this indicates that the code is not selectable ('Abstract') |
| Display | The display (used in the display element of a Coding ). If there is no display, implementers should not simply display the code, but map the concept into their application |
| Definition | An explanation of the meaning of the concept |
| Comments | Additional notes about how to use the code |